THERAPY DOSSIER · th-4204b2a70617

Paxilline

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24836752 ↗2014Reported benefit

Pharmacological blockade of the MaxiK channel attenuates experimental acute pancreatitis and associated lung injury in rats.

RatChemical/toxinWistarmaleCompared as pre-treatment and therapeutic administration after induction

Model: Sodium taurocholate induced acute pancreatitis with secondary lung injury

Paxilline attenuated pancreatitis and lung injury with lower inflammatory cytokines and lung myeloperoxidase, and pre-treatment was more effective than therapeutic dosing.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…